SOLENO THERAPEUTICS INC - SLNO
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | Sr. VP of Clinical Development | S | D | 488.0 | 31.7187 | 15,478.73 | 39,823.0 | View | |
| Mar 31, 2026 | Sr. VP of Clinical Development | S | D | 1,838.0 | 31.0384 | 57,048.58 | 40,311.0 | View | |
| Mar 31, 2026 | Sr. VP of Clinical Development | S | D | 4,256.0 | 30.037 | 127,837.47 | 42,149.0 | View | |
| Mar 31, 2026 | Chief Commercial Officer | S | D | 558.0 | 31.7187 | 17,699.03 | 64,507.0 | View | |
| Mar 31, 2026 | Chief Commercial Officer | S | D | 2,100.0 | 31.0384 | 65,180.64 | 65,065.0 | View | |
| Mar 31, 2026 | Chief Commercial Officer | S | D | 4,864.0 | 30.037 | 146,099.97 | 67,165.0 | View | |
| Mar 04, 2026 | CHIEF FINANCIAL OFFICER | M | A | 67,660.0 | 0.0 | 0.0 | 67,660.0 | View | |
| Mar 04, 2026 | CHIEF FINANCIAL OFFICER | A | A | 39,200.0 | 0.0 | 0.0 | 39,200.0 | View | |
| Jan 23, 2026 | CHIEF EXECUTIVE OFFICER | A | A | 131,400.0 | 0.0 | 0.0 | 131,400.0 | View | |
| Jan 23, 2026 | CHIEF EXECUTIVE OFFICER | A | A | 114,200.0 | 0.0 | 0.0 | 583,656.0 | View | |
| Jan 23, 2026 | SEE REMARKS | A | A | 11,900.0 | 0.0 | 0.0 | 11,900.0 | View | |
| Jan 23, 2026 | SEE REMARKS | A | A | 10,400.0 | 0.0 | 0.0 | 22,702.0 | View | |
| Jan 23, 2026 | Sr. VP of Clinical Development | A | A | 11,900.0 | 0.0 | 0.0 | 11,900.0 | View | |
| Jan 23, 2026 | Sr. VP of Clinical Development | A | A | 10,400.0 | 0.0 | 0.0 | 46,405.0 | View | |
| Jan 23, 2026 | Chief Development Officer | A | A | 4,700.0 | 0.0 | 0.0 | 4,700.0 | View | |
| Jan 23, 2026 | Chief Development Officer | A | A | 4,100.0 | 0.0 | 0.0 | 20,171.0 | View | |
| Jan 23, 2026 | CHIEF FINANCIAL OFFICER | A | A | 32,800.0 | 0.0 | 0.0 | 32,800.0 | View | |
| Jan 23, 2026 | CHIEF FINANCIAL OFFICER | A | A | 28,600.0 | 0.0 | 0.0 | 131,763.0 | View | |
| Jan 23, 2026 | Chief Commercial Officer | A | A | 32,800.0 | 0.0 | 0.0 | 32,800.0 | View | |
| Jan 23, 2026 | Chief Commercial Officer | A | A | 28,600.0 | 0.0 | 0.0 | 72,029.0 | View | |
| Jan 23, 2026 | Chief Business Officer | A | A | 4,000.0 | 0.0 | 0.0 | 4,000.0 | View | |
| Jan 23, 2026 | Chief Business Officer | A | A | 3,500.0 | 0.0 | 0.0 | 17,786.0 | View | |
| Jan 23, 2026 | SEE REMARKS | A | A | 11,900.0 | 0.0 | 0.0 | 11,900.0 | View | |
| Jan 23, 2026 | SEE REMARKS | A | A | 10,400.0 | 0.0 | 0.0 | 37,639.0 | View | |
| Dec 17, 2025 | CHIEF EXECUTIVE OFFICER | G | D | 100,000.0 | 0.0 | 0.0 | 469,456.0 | View | |
| Dec 17, 2025 | CHIEF EXECUTIVE OFFICER | F | D | 7,620.0 | 49.95 | 380,619.0 | 569,456.0 | View | |
| Dec 17, 2025 | SEE REMARKS | F | D | 904.0 | 49.95 | 45,154.8 | 12,302.0 | View | |
| Dec 17, 2025 | Sr. VP of Clinical Development | F | D | 812.0 | 49.95 | 40,559.4 | 36,005.0 | View | |
| Dec 17, 2025 | CHIEF FINANCIAL OFFICER | F | D | 2,013.0 | 49.95 | 100,549.35 | 103,163.0 | View | |
| Dec 17, 2025 | Chief Commercial Officer | F | D | 1,922.0 | 49.95 | 96,003.9 | 43,429.0 | View | |
| Dec 17, 2025 | SEE REMARKS | F | D | 904.0 | 49.95 | 45,154.8 | 27,239.0 | View | |
| Nov 19, 2025 | Chief Business Officer | M | A | 64,286.0 | 0.0 | 0.0 | 64,286.0 | View | |
| Nov 19, 2025 | Chief Business Officer | A | A | 14,286.0 | 0.0 | 0.0 | 14,286.0 | View | |
| Nov 12, 2025 | Chief Development Officer | M | A | 72,321.0 | 0.0 | 0.0 | 72,321.0 | View | |
| Nov 12, 2025 | Chief Development Officer | A | A | 16,071.0 | 0.0 | 0.0 | 16,071.0 | View | |
| Oct 14, 2025 | — | A | A | 10,046.0 | 0.0 | 0.0 | 10,046.0 | View |